title: Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Inokura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Onishi
authors.forename: Kenji
authors.initials: K
authors.lastname: Shimosegawa
authors.forename: Yoko
authors.initials: Y
authors.lastname: Okitsu
authors.forename: Yuna
authors.initials: Y
authors.lastname: Katsuoka
authors.forename: Tohru
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Noriko
authors.initials: N
authors.lastname: Fukuhara
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ishizawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D060830:Consolidation Chemotherapy; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases